CO-1686 intermediate 1(CAS#1374507-25-1)

 CO-1686 intermediate 1(CAS#1374507-25-1)

pharmachologic effect

Mechanism of action: CO-1686 is a novel, oral, covalent (irreversible) targeted inhibitor of epidermal growth factor receptor (EGFR) mutations, capable of inhibiting key activating mutations and T790 resistance mutations without affecting wild-type EGFR signaling.
Applications: Mainly used for the treatment of patients with non-small cell lung cancer (NSCLC) carrying the initial activation EGFR mutation and the major resistance mutation T790M.
Synthesis method: 1-(3-methoxy-4-aminophenyl)-4-acetylpiperazine, 2,4-dichloro-5-trifluoromethylpyrimidine and 3-nitroaniline were condensed, reduced and amidified with piperazine to obtain N-(3-(2-chloro-5-trifluoromethyl-pyrimidine-4-amino)phenyl) acrylamide, and the two were then condensed to obtain CO-1686.